Furthermore, MLH1 and MSH2 variants heralding Lynch syndrome or CMMRD syndrome are also considered actionable in a way of further surveillance and potential use of immune checkpoint inhibitors. This evidence concerns the gene MLH1 and Lynch syndrome.